ERBB2 and breast cancer: In front line of metastatic BC median PFS found in our study was slightly lower than that of the E2100 study,24 but similar to that of the pooled analysis of three randomized phase III trials in HER2-negative patients34: this may be because of the existence of a large group of patients with poor prognosis factors such as triple negative subtype35 or inflammatory BC.36